Wyeth Pharmaceuticals and Santaris Pharma Announce Strategic Alliance to Develop RNA-based Medicines
Collegeville, Pa., & Hoersholm, Denmark — Wyeth Pharmaceuticals, a division of Wyeth (NYSE:WYE), and Santaris Pharma today announced that the companies have entered into a worldwide strategic alliance to discover, develop and commercialize new medicines based on Santaris Pharma’s proprietary Locked Nucleic Acid (LNA) drug platform, which allows specific targeting and regulation of microRNAs (miRNAs) and messenger RNAs (mRNAs) as a means to affect gene expression mediated by the targeted RNAs.
Under the terms of the agreement, Santaris Pharma will receive an upfront payment of $7 million in cash and Wyeth will make a $10 million equity investment in Santaris Pharma. Santaris Pharma may receive further milestone payments of up to $83 million for each of 10 potential targets. In addition, Santaris Pharma would receive royalties on the worldwide sales of all products arising from the alliance. The term of the research portion of the collaboration is three years. Wyeth has the right to extend the research portion up to two additional years.
Wyeth will select the RNA targets against which Santaris Pharma will use their proprietary LNA drug platform to generate unique drug candidates. Wyeth will be responsible for the development and commercialization of products arising from the alliance.
“With this alliance Wyeth explores a fourth platform technology targeting RNAs, which complements our expertise in small molecules, vaccines and protein-based therapeutics,”
says Mikael Dolsten, President, Wyeth Research.
“This will increase our ability to develop and bring to market innovative, high-value medicines that have the potential to address significant unmet needs in critical therapeutic areas.”
“We are delighted to welcome Wyeth as a new major partner,” says Søren Tulstrup, President and CEO of Santaris Pharma.
“This strategic alliance further consolidates Santaris Pharma’s leading position in the rapidly evolving RNA-based therapeutic field. The scope of this collaboration demonstrates the utility of Santaris Pharma’s proprietary LNA Drug Platform for developing new therapies targeting RNAs.”
About the Locked Nucleic Acid Drug Platform
There are two major classes of RNA targets for this collaboration. messengerRNAs and microRNAs. miRNAs are recognized as important elements in regulation of gene expression in both normal and diseased cells, whereas mRNAs are translated into the proteins that determine all aspects of cell identity and behavior. Santaris Pharma’s proprietary technology allows for the discovery of molecules that specifically and potently inhibit the function ofeither of these classes of RNA.
The Locked Nucleic Acid-based technology developed by Santaris Pharma creates synthetic chemical versions (LNAs) of the normal nucleic acid building blocks of RNAs. These LNAs improve the drug-like qualities ofresulting therapeutics, called oligonucleotides, by increasing resistance to metabolism, increasing half-life and improving tissue uptake. The LNA-based therapeutics also demonstrate improved binding affinity to their target RNA, which increases potency many-fold over other nucleotide therapeutics.
About Santaris Pharma
Santaris Pharma is a privately held biopharmaceutical company with exclusive pharmaceutical rights to the LNA Drug Platform used to develop new classes of RNA medicines targeting mRNAs and miRNAs associated with disease. Santaris Pharma’s drug discovery engine provides fast and efficient generation of lead LNA drug candidates. The Company’s own research and development activities focus on microRNAs, infectious diseases and metabolic disorders. Santaris Pharma has repeatedly validated the LNA Drug Platform through partnerships with major pharmaceutical companies. Santaris Pharmawas founded in 2003, is based in Denmark, and the Company and its partners currently have three compounds in clinical development and and two more in late preclinical development. Since 2006 the Company has raised more than 60 million Euros through private financing and corporate partnerships.
About Wyeth Pharmaceuticals
Wyeth Pharmaceuticals, a division of Wyeth, has leading products in the areas of women’s health care, infectious disease, gastrointestinal health, central nervous system, inflammation, transplantation, hemophilia, oncology, vaccines and nutritional products.Wyeth is one of the world’s largest research-driven pharmaceutical and health care products companies. It is a leader in the discovery, development, manufacturing and marketing of pharmaceuticals, vaccines, biotechnologyproducts, nutritionals and non-prescription medicines that improve the quality of life for people worldwide. The Company’s major divisions include Wyeth Pharmaceuticals, Wyeth Consumer Healthcare and Fort Dodge Animal Healt.
Wyeth Pharmaceuticals (484) 865-1346
Cell: +45 20488384
The statements in this press release that are not historical facts are forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include, without limitation, the inherent uncertainty of the timing and success of, and expense associated with, research, development, regulatory approval and commercialization of our products and pipeline products; government cost-containment initiatives; restrictions on third-party payments for our products; substantial competition in our industry, including from branded and generic products; emerging data on our products and pipeline products; the importance of strong performance from our principal products and our anticipated new product introductions; the highly regulated nature of our business; product liability, intellectual property and other litigation risks and environmental liabilities; uncertainty regarding our intellectual property rights and those of others; difficulties associated with, and regulatory compliance with respect to, manufacturing of our products; risks associated with our strategic relationships; economic conditions including interest and currency exchange rate fluctuations; changes in generally accepted accounting principles; trade buying patterns; the impact of legislation and regulatory compliance; risks and uncertainties associated with global operations and sales; and other risks and uncertainties, including those detailed from time to time in our periodic reports filed with the Securities and Exchange Commission, including our current reports on Form 8-K, quarterly reports on Form 10-Q and annual report on Form 10-K, particularly the discussion under the caption “Item 1A, Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2007, which was filed with the Securities and Exchange Commission on February 29, 2008. The forward-looking statements in this press release are qualified by these risk factors. We assume no obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise.